Vitreo Pharma is a developmental stage company that utilizes a polypharmacology strategy to generate our lead, first in class asset VT-1001, with dual anti-glycation and pantropic anti-angiogenic actions and developed as a topical ocular prodrug nano-formulation targeting both front and back of eye diabetic eye diseases, diabetic retinopathy and keratopathy, along with pterygium and corneal neovascularization. Currently at IND-enabling stage. 

Vitreo Pharma Logo



Event details

Date: June 8 - 12, 2020

Event contact

Patricia Cosgrove
Area Director
USA: Life Sciences


34 in total